Genprex, Inc.

GNPX

$4.04

Name : Genprex, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $6,592,637.00

EPSttm : 42.5

Genprex, Inc.

$4.04

8.80%

$0.39

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

4.03

Target Price

375

Analyst Recom

Performance Q

-52.5

Relative Volume

0.29

Beta

-0.75

Ticker: GNPX

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	GNPX	0.28	N/A	N/A	0
2025-10-21	GNPX	11.18	N/A	N/A	0
2025-10-22	GNPX	10.88	N/A	N/A	0
2025-10-23	GNPX	9.16	N/A	N/A	0
2025-10-24	GNPX	9.61	N/A	N/A	0
2025-10-27	GNPX	8.67	N/A	N/A	0
2025-10-28	GNPX	6.99	N/A	N/A	0
2025-10-29	GNPX	6.65	N/A	N/A	0
2025-10-30	GNPX	6.265	N/A	N/A	0
2025-10-31	GNPX	5.81	N/A	N/A	0
2025-11-03	GNPX	5.28	N/A	N/A	0
2025-11-04	GNPX	4.71	N/A	N/A	0
2025-11-05	GNPX	5.86	N/A	N/A	0
2025-11-06	GNPX	4.7	N/A	N/A	0
2025-11-07	GNPX	4.22	N/A	N/A	0
2025-11-10	GNPX	3.93	N/A	N/A	0
2025-11-11	GNPX	4.0108	N/A	N/A	0
2025-11-12	GNPX	4.65	N/A	N/A	0
2025-11-13	GNPX	4.09	N/A	N/A	0
2025-11-14	GNPX	4.46	N/A	N/A	0
2025-11-17	GNPX	4	N/A	N/A	0
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	GNPX	0.28	-	-	-
2025-10-21	GNPX	10.85	-	-	-
2025-10-22	GNPX	10.96	-	-	-
2025-10-23	GNPX	9.02	-	-	-
2025-10-24	GNPX	9.57	-	-	-
2025-10-27	GNPX	8.68	-	-	-
2025-10-28	GNPX	6.99	-	-	-
2025-10-29	GNPX	6.63	-	-	-
2025-10-30	GNPX	6.27	-	-	-
2025-10-31	GNPX	5.77	-	-	-
2025-11-03	GNPX	5.34	-	-	-
2025-11-04	GNPX	4.72	-	-	-
2025-11-05	GNPX	5.87	-	-	-
2025-11-06	GNPX	4.69	-	-	-
2025-11-07	GNPX	4.21	-	-	-
2025-11-10	GNPX	4.00	-	-	-
2025-11-11	GNPX	4.05	-	-	-
2025-11-12	GNPX	4.59	-	-	-
2025-11-13	GNPX	4.09	-	-	-
2025-11-14	GNPX	4.37	-	-	-
2025-11-17	GNPX	4.03	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	GNPX	0.00	3.70	4.26
2025-10-21	GNPX	0.00	3.70	4.26
2025-10-22	GNPX	0.00	3.70	4.29
2025-10-23	GNPX	0.00	3.70	4.29
2025-10-24	GNPX	0.00	3.70	0
2025-10-27	GNPX	0	0	0
2025-10-28	GNPX	0	0	4.57
2025-10-29	GNPX	0.00	0	4.57
2025-10-30	GNPX	0.00	0	4.57
2025-10-31	GNPX	0.00	0	0
2025-11-03	GNPX	0.00	0	0
2025-11-04	GNPX	0.00	0	2.82
2025-11-05	GNPX	0.00	0	2.82
2025-11-06	GNPX	0.00	0	2.82
2025-11-07	GNPX	0.00	0	2.84
2025-11-10	GNPX	0.00	0	3.16
2025-11-11	GNPX	0.00	0	3.16
2025-11-12	GNPX	0.00	0	18.69
2025-11-13	GNPX	0.00	0	18.69
2025-11-14	GNPX	0.00	0	18.69
2025-11-17	GNPX	0.00	0	0
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.17

Avg. EPS Est. Current Quarter

-0.42

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

-0.75

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

100

Max Drawdown 5-Year %

-100

Target Price

375

P/E

Forward P/E

PEG

P/S

P/B

5.28

P/Free Cash Flow

EPS

-47.66

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

-1.15

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.29

Return on Equity vs Sector %

-1249.6

Return on Equity vs Industry %

-1234.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Genprex, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 15

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

stock quote shares GNPX – Genprex, Inc. Stock Price stock today

news today GNPX – Genprex, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch GNPX – Genprex, Inc. yahoo finance google finance

stock history GNPX – Genprex, Inc. invest stock market

stock prices GNPX premarket after hours

ticker GNPX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: GNPX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y